BACKGROUND: Treatment of splenic marginal zone lymphoma (SMZL) patients is not standardized. Recent data suggest that rituximab is highly effective and could be considered as initial therapy. AIM: To assess the efficacy of rituximab monotherapy in a large series of patients with SMZL and compare these results with splenectomy results. METHODS: The studied population included 85 patients. Fifty-eight received rituximab at a dose of 375 mg/m2 per week for 6 weeks as induction followed by maintenance at the same dose every 2 months for 1-2 years, whereas 27 patients were treated using splenectomy only. RESULTS: The overall response rate to rituximab 2 months after the end of induction was 95% (complete response [CR], 45%; unconfirmed CR, 26%; partial response, 24%). The median times to hematologic and clinical response were 2 weeks and 3 weeks, respectively. Forty-three of 55 patients already completed the maintenance phase: 28 sustained their initial response, 14 improved their response, and one progressed. Eighty-five percent of splenectomized patients responded, and two were treated with rituximab as consolidation after splenectomy and achieved a CR. The 5-year overall and progression-free survival (PFS) rates for rituximab-treated and splenectomized patients were 92% and 77% (p = .09) and 73% and 58% (p = .06), respectively. Furthermore, maintenance therapy with rituximab resulted in a longer duration of response (at 5 years, PFS was 84% for patients receiving maintenance and 36% for patients without maintenance, p <.0001). CONCLUSIONS: Rituximab is a very effective and well-tolerated therapy and may be substituted for splenectomy as the first-line treatment of choice for patients with SMZL.
BACKGROUND: Treatment of splenic marginal zone lymphoma (SMZL) patients is not standardized. Recent data suggest that rituximab is highly effective and could be considered as initial therapy. AIM: To assess the efficacy of rituximab monotherapy in a large series of patients with SMZL and compare these results with splenectomy results. METHODS: The studied population included 85 patients. Fifty-eight received rituximab at a dose of 375 mg/m2 per week for 6 weeks as induction followed by maintenance at the same dose every 2 months for 1-2 years, whereas 27 patients were treated using splenectomy only. RESULTS: The overall response rate to rituximab 2 months after the end of induction was 95% (complete response [CR], 45%; unconfirmed CR, 26%; partial response, 24%). The median times to hematologic and clinical response were 2 weeks and 3 weeks, respectively. Forty-three of 55 patients already completed the maintenance phase: 28 sustained their initial response, 14 improved their response, and one progressed. Eighty-five percent of splenectomized patients responded, and two were treated with rituximab as consolidation after splenectomy and achieved a CR. The 5-year overall and progression-free survival (PFS) rates for rituximab-treated and splenectomized patients were 92% and 77% (p = .09) and 73% and 58% (p = .06), respectively. Furthermore, maintenance therapy with rituximab resulted in a longer duration of response (at 5 years, PFS was 84% for patients receiving maintenance and 36% for patients without maintenance, p <.0001). CONCLUSIONS:Rituximab is a very effective and well-tolerated therapy and may be substituted for splenectomy as the first-line treatment of choice for patients with SMZL.
Authors: Apostolia M Tsimberidou; Daniel Catovsky; Ellen Schlette; Susan O'Brien; William G Wierda; Hagop Kantarjian; Guillermo Garcia-Manero; Sijin Wen; Kim-Anh Do; Susan Lerner; Michael J Keating Journal: Cancer Date: 2006-07-01 Impact factor: 6.860
Authors: Elena Ruiz-Ballesteros; Manuela Mollejo; Antonia Rodriguez; Francisca I Camacho; Patrocinio Algara; Nerea Martinez; Marina Pollán; Abel Sanchez-Aguilera; Javier Menarguez; Elias Campo; Pedro Martinez; Marisol Mateo; Miguel A Piris Journal: Blood Date: 2005-05-24 Impact factor: 22.113
Authors: Christina Kalpadakis; Gerassimos A Pangalis; Evangelia Dimitriadou; Maria K Angelopoulou; Marina P Siakantaris; Marie-Christine Kyrtsonis; Maria Ximeris; Tatiana Tzenou; Sotirios Sahanas; Xanthi Yiakoumis; Eleni A Papadaki; Panayiotis Panayiotidis; Theodoros Vassilakopoulos Journal: Anticancer Res Date: 2009-05 Impact factor: 2.480
Authors: E Matutes; D Oscier; C Montalban; F Berger; E Callet-Bauchu; A Dogan; P Felman; V Franco; E Iannitto; M Mollejo; T Papadaki; E D Remstein; A Salar; F Solé; K Stamatopoulos; C Thieblemont; A Traverse-Glehen; A Wotherspoon; B Coiffier; M A Piris Journal: Leukemia Date: 2007-12-20 Impact factor: 11.528
Authors: C Kalpadakis; G A Pangalis; M N Dimopoulou; T P Vassilakopoulos; M-C Kyrtsonis; P Korkolopoulou; F N Kontopidou; M P Siakantaris; E M Dimitriadou; S I Kokoris; P Tsaftaridis; E Plata; M K Angelopoulou Journal: Hematol Oncol Date: 2007-09 Impact factor: 5.271
Authors: T Srikumar; M Markow; B Centeno; S Hoffe; J Tao; H Fernandez; J Strosberg; D Shibata Journal: Curr Oncol Date: 2016-02-18 Impact factor: 3.677
Authors: Marina Parry; Matthew Jj Rose-Zerilli; Viktor Ljungström; Jane Gibson; Jun Wang; Renata Walewska; Helen Parker; Anton Parker; Zadie Davis; Anne Gardiner; Neil McIver-Brown; Christina Kalpadakis; Aliki Xochelli; Achilles Anagnostopoulos; Claudia Fazi; David Gonzalez de Castro; Claire Dearden; Guy Pratt; Richard Rosenquist; Margaret Ashton-Key; Francesco Forconi; Andrew Collins; Paolo Ghia; Estella Matutes; Gerassimos Pangalis; Kostas Stamatopoulos; David Oscier; Jonathan C Strefford Journal: Clin Cancer Res Date: 2015-03-16 Impact factor: 12.531
Authors: Sean I Tracy; Melissa C Larson; Andrew L Feldman; Matthew J Maurer; Anne J Novak; Susan L Slager; Jose C Villasboas; Cristine Allmer; Thomas M Habermann; Umar Farooq; Sergei Syrbu; James R Cerhan; Brian K Link Journal: Am J Hematol Date: 2019-04-10 Impact factor: 10.047